The pattern is explainable: The people experiencing transformative outcomes are the ones whose obesity was being driven primarily by the mechanisms GLP-1 actually targets: inflammation, gut signaling, neurological dysregulation
She began her career as an intern in the fashion closet at Cosmopolitan where she worked her way up to Senior Sex & Relationships Editor
Large meals overwhelm a stomach that is already emptying slowly
Metformin: Co-administration of multiple twice-daily doses of sitagliptin with metformin, an OCT substrate, did not meaningfully alter the pharmacokinetics of metformin in patients with type 2 diabetes
In a market where persistence is a major commercial problem, dosing convenience could become a valuable differentiator
Pattern 2: The Non-Responder (approximately 15% of switchers) Weight loss plateaus or slows despite escalating to Zepbound 12.5 to 15 mg May report initial response at 5 to 7.5 mg that fades by week 16 to 20 Often have underlying metabolic factors (severe insulin resistance, hypothyroidism, medications causing weight gain) For this group, the switch to tirzepatide does not solve the core problem
